Home > Dermatology > SPIN 2019 > Advances in Therapy > Favourable safety profile of long-term use of ixekizumab

Favourable safety profile of long-term use of ixekizumab

Expert
Prof. Kristian Reich, Georg-August-University Göttingen, Germany
Conference
SPIN 2019

Ixekizumab (IL-17A blocker) shows a consistent long-term safety profile in treating psoriasis with 5+ years of drug exposure in a large pooled database including 17,003 patient-years of exposure [1].

Results of this integrated analysis of 11 clinical trials were presented by Prof. Kristian Reich (Georg-August-University Göttingen, Germany), who pointed out that when it comes to drugs with which we only have limited experience, it is essential to capture data about safety as early as possible from as many patients as possible. A pooled analysis was performed of 11 controlled and uncontrolled phase 1-3 studies using ixekizumab in psoriasis totalling >17,000 patient years of exposure.

Prof. Reich: “The absolute numbers of safety events are actually very low here; infections are among the most frequent, but you have to treat 100 patients for 1 year to see 1 event, and this is in the ballpark with other targeted therapies.” The incidence rate of serio...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on